Английская Википедия:HPTN 083
Шаблон:Short description Шаблон:Infobox
HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS.
The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen.[1]
HPTN 083 is the first large scale phase III clinical trial of cabotegravir.[2]
In February 2016 researchers presented the results of the ECLAIR study.[3] That study examined cabotegravir and found no serious safety concerns.[3]
The research is a collaboration of Gilead Sciences, HIV Prevention Trials Network, ViiV Healthcare, National Institute of Allergy and Infectious Diseases.[4]
Local study sites will include John H. Stroger Jr. Hospital of Cook County.[5]
On May 18, 2020, HPTN announced that the long-acting injections had been found to be a highly effective treatment.[6]
References
External links
- official page at ClinicalTrials.gov
- HPTN 083: The HIV Life Cycle With Cabotegravir, a video provided by HPTN
